
Oliver Mulherin is an Australian software engineer predominantly recognized for his contributions to the technology sector and his relationship with Sam Altman, the CEO of OpenAI. Mulherin has been involved in various AI projects and gained prominence through his professional work and as Altman's partner. His career highlights include significant roles at companies such as Meta (formerly Facebook), IOTA Foundation, and SPARK Neuro. His recent involvement extends to emerging ventures, notably investing in the startup Preventive, which focuses on gene-editing technologies.
In recent years, Oliver Mulherin has been at the forefront of multiple significant personal and professional developments:
| Attribute | Information |
|---|---|
| Full Name | Oliver Louis Mulherin |
| Born | 1993, Melbourne, Australia |
| Nationality | Australian |
| Occupation | Software Engineer, Investor |
| Known For | Partner of Sam Altman, AI Projects |
| Net Worth | Estimated at $5-10 million in 2025 |
| Education | Bachelor of Computer Science, University of Melbourne |
Oliver Mulherin was born in Melbourne, Australia, in 1993. He developed an early interest in technology during his school years, attending John Monash Science School where he honed his science and technology skills. Pursuing higher education, Mulherin graduated with a Bachelor of Computer Science degree from the University of Melbourne in 2016. His academic endeavors equipped him with the foundational skills that propelled his career as a software engineer.
Oliver Mulherin began his professional journey with an internship at Vital-Sim in Calgary, which laid the groundwork for his software development skills. Subsequently, he co-founded PROPL in Melbourne in 2015. Mulherin's career trajectory includes significant positions at:
As of 2025, Oliver Mulherin is known for his investment in the gene-editing startup Preventive, which seeks to eliminate hereditary diseases. This venture aligns with Mulherin's interest in integrating innovative technology solutions to solve complex human challenges. His impact extends beyond his professional achievements as he shares plans with Sam Altman to contribute to genetic research aimed at preventing diseases at a hereditary level.
Oliver Mulherin's journey is marked by influential roles within the tech industry and his partnership with OpenAI's CEO, Sam Altman. While his professional contributions to AI and software engineering are commendable, his recent endeavors, particularly his investment in Preventive, illustrate a commitment to leveraging technology for societal benefit. As he continues to balance personal commitments and professional aspirations, Mulherin's future in tech innovation presents the potential for significant advancements in both AI and genetic technology.